First Patient Receives Gene Therapy for Ultra-Rare NEDAMSS Disease in Record 13-Month Timeline
核心洞察
Elly's Team (搜索), a parent-led foundation, achieved FDA approval and successfully dosed the first patient with IRF2BPL gene replacement therapy (搜索) for NEDAMSS (搜索) in just 13 months after diagnosis.
Charles River Laboratories partnered with Elly's Team (搜索) through their Cell and Gene Therapy Accelerator Program to manufacture critical plasmid DNA starting materials for the Phase I clinical trial.
NEDAMSS (搜索) is an ultra-rare neurodevelopmental disorder caused by IRF2BPL (搜索) gene mutations, affecting fewer than 150 diagnosed cases worldwide and causing regression in motor skills, speech, and seizures.
A parent-led foundation has achieved a remarkable milestone in rare disease treatment, successfully dosing the first patient with gene replacement therapy for an ultra-rare neurodevelopmental disorder in just 13 months from diagnosis to treatment. Elly's Team (搜索), founded by Michelle and Dan Krueger after their daughter's diagnosis, partnered with Charles River Laboratories to manufacture critical starting materials for their groundbreaking Phase I clinical trial targeting NEDAMSS (搜索).
On April 3, 2025, Elly became the first child to receive IRF2BPL gene replacement therapy (搜索), marking a historic achievement for the ultra-rare disease community. The FDA signed off on the treatment in March 2025, following an accelerated development timeline that compressed typical drug development processes.
Ultra-Rare Disease Affects Fewer Than 150 Patients Worldwide
NEDAMSS (搜索) (Neurodevelopmental Disorder with Regression, Abnormal Movements, Loss of Speech, and Seizures (搜索)) is caused by mutations in the Interferon regulatory factor 2 binding protein-like (搜索) (IRF2BPL (搜索)) gene. Fewer than 150 cases have been diagnosed worldwide, making it an ultra-rare condition with no previously available treatments.
The regressive neurodevelopmental disorder affects the central nervous system and can impact motor skills, speech, eating, and eyesight, among other functions. Patients often experience seizures as part of the disease progression, creating significant challenges for affected families.
Strategic Partnership Accelerates Manufacturing Timeline
Charles River Laboratories partnered with Elly's Team (搜索) through their Cell and Gene Therapy (CGT) Accelerator Program (CAP), providing established gene therapy CDMO capabilities and advisory services. The collaboration focused on manufacturing critical starting materials needed for the Phase I clinical trial.
"The opportunity to work with Elly's Team (搜索) aligns closely with our core mission: supporting the development of potentially curative treatments for Elly and other patients suffering from ultra-rare diseases with no known treatment," said Kerstin Dolph, Corporate Senior Vice President, Global Manufacturing, Charles River.
Advanced Manufacturing Platform Reduces Production Time
Elly's Team (搜索) leveraged Charles River's established plasmid platform, eXpDNA™, and premier expertise in plasmid DNA production. The program utilized phase-appropriate High Quality (HQ) plasmid manufacturing that employs good manufacturing practices (GMP) principles to produce plasmids with rapid turnaround times.
The collaboration also incorporated Charles River's off-the-shelf AAV Rep/Cap plasmids, designed to streamline adeno-associated virus (AAV)-based gene therapy programs. These ready-to-use plasmid products reduced production time and improved supply chain efficacy, ultimately reducing manufacturing efforts by up to 66 percent.
The plasmid products are manufactured and released with CMC guidance according to batch production records, complete with a Certificate of Analysis (COA) to support Investigational New Drug (IND) and Clinical Trial Application (CTA) filings.
Record-Breaking Development Timeline
Founded in 2024 by Elly's parents, Elly's Team (搜索) assembled experts in gene therapy and drug discovery to advance multiple development steps simultaneously. The foundation funded additional research to understand the disease mechanism and effects on the body while conducting safety and toxicity studies and manufacturing the therapeutic.
The team navigated the FDA approval process to obtain Investigational New Drug (IND) approval in just 13 months after Elly's diagnosis, demonstrating the potential for accelerated rare disease drug development when resources and expertise are strategically coordinated.
"We want to express our deepest gratitude to all members of Elly's Team (搜索) who made this incredible treatment a reality, including Charles River whose partnership and expertise has undoubtedly contributed to the advancement of our gene therapy program," stated Michelle Kruger, Elly's mother and Co-Founder of Elly's Team. "This achievement marks a major milestone, not only for our family but also for the entire IRF2BPL (搜索) community. In the future, another family will sit in the hospital and receive the same diagnosis, but their doctor will tell them there is a path to treatment."